Larazotide
Also known as: Larazotide acetate, AT-1001, INN-202
Larazotide is an investigational peptide studied in clinical trials for coeliac disease, where it has been examined as a possible gut-barrier-related agent. It is not an approved medicine in Australia.
- Category
- Gut Health
- Reported half-life
- Reported to act locally with minimal systemic absorption; systemic half-life not well established
- Common forms
- Oral capsule formulations (investigational / clinical-trial use)
- Research status
- Investigational; studied in clinical trials for coeliac disease. It is not an approved medicine in Australia, and late-stage trial results have been mixed.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported to be studied in relation to intestinal tight-junction (gut-barrier) function
- Reported to have been investigated for coeliac-disease-related symptoms in clinical trials
- Reported to be studied as a non-absorbed, gut-targeted peptide
How it is reported to work
Larazotide is proposed to act locally in the gut as a tight-junction regulator that may influence intestinal permeability. These proposed mechanisms come from clinical and laboratory research in coeliac disease, but outcomes from late-stage trials have been mixed and the mechanism should be regarded as investigational rather than established.
Background
Larazotide (larazotide acetate, also known by codes such as AT-1001) is an investigational peptide studied in clinical trials for coeliac disease, where it has been examined in relation to the gut barrier. This page is educational information, not medical advice, and the effects described below are reported claims, not established facts.
What the research shows
Larazotide has been studied in laboratory work and in clinical trials, including for coeliac disease. Some earlier studies suggested effects on symptoms or gut permeability, but later-stage trial results have been mixed and it has not gained approval.
| Evidence type | Status |
|---|---|
| Laboratory studies | Present |
| Early clinical trials | Some signal reported |
| Late-stage clinical trials | Mixed results |
| Australian approval | None |
What people use it for (reported)
Online, people report interest in Larazotide in connection with coeliac disease and gut-barrier topics. These are reported claims, not validated or approved outcomes, and nothing here should be read as encouragement to use it.
Things to be aware of
Larazotide is investigational and is not an approved medicine in Australia. Its safety and efficacy outside controlled trials are not established, and grey-market preparations cannot be verified for purity or identity by sight. If you have coeliac disease or another gut-health concern, the appropriate step is to speak with a qualified healthcare professional. This article does not recommend obtaining or using Larazotide. All effects described here remain reported claims, not established facts.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported in clinical trials to be studied for coeliac-disease-related symptoms
- Reported interest in regulating intestinal tight junctions (gut barrier)
- Reported to act locally in the gut with minimal systemic absorption
- Reported as taken before meals in the trial setting
Common side effects
- Reported abdominal discomfort or bloating
- Reported nausea
- Reported headache in trials
- Reported changes in bowel habit
Rare / serious side effects
- Reported allergic or hypersensitivity-type reactions
- Reported lack of meaningful benefit, as late-stage trials were mixed
- Reported unpredictable effects from unverified grey-market product
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of Larazotide. Listed so you can make an informed decision, not to suggest any use is safe.
- Reported self-dosing for coeliac or gut symptoms in place of a medically guided gluten-free diet
- Reported use of unverified self-sourced product whose identity and purity cannot be confirmed
- Reported dosing outside the per-meal pattern studied in trials
- Reported reliance on it as a treatment despite mixed late-stage trial results
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Reported as a per-dose, before-meals agent with any symptom effects assessed over weeks rather than acutely.
First effects
reported per-dose, taken before a meal in trials
Noticeable change
reported symptom changes assessed over weeks of regular dosing
Clear results
reported over an extended trial period; benefit not consistently established
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take Larazotide. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Oral capsule (non-absorbed, gut-targeted; investigational) |
|---|---|
| Typical reported dose | Reported around 0.5 mg (500 mcg) per dose in clinical trials |
| Frequency | Reported three times daily, taken before meals, in the trial setting |
| Cycle length | Reported over trial periods of several weeks; no established consumer cycle |
Commonly reported in trials as an oral capsule taken before meals over a period of weeks; this is reported information, not advice.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Safety notes
Larazotide is investigational and is not an approved medicine in Australia. Its safety and efficacy outside controlled trials are not established, and grey-market product purity cannot be verified by consumers. Anyone with coeliac disease or another gut-health concern should consult a qualified healthcare professional.